Browsing Tag
semaglutide
39 posts
Are compounded weight-loss drugs the next opioid crisis? Inside the unregulated boom of off-label GLP-1s
Are GLP-1 weight-loss drugs like semaglutide fueling a new safety crisis? Explore the unregulated boom in compounded injections and FDA’s crackdown.
GLP-1 crackdown intensifies: What FDA’s new green list means for tirzepatide safety
The FDA’s new GLP-1 green list aims to block illegal semaglutide and tirzepatide imports. Find out how it could reshape the compounding pharmacy landscape.
Novo Nordisk stock rises on Wegovy STEER data: Can semaglutide cement its lead over Eli Lilly?
Novo Nordisk shares gained after STEER study showed Wegovy cut heart risks by 57% over tirzepatide. Find out why semaglutide may lead the GLP-1 race.
Wegovy cuts cardiovascular event risk by over half vs tirzepatide—real-world data raises Novo Nordisk lead
Discover how Novo Nordisk’s Wegovy reduced heart attack, stroke, and death risk by 57% vs tirzepatide in real-world study. Read the STEER findings now.
Ascletis Pharma completes dosing in U.S. ASC47-semaglutide study for obesity treatment
Ascletis Pharma completes dosing in its ASC47-semaglutide obesity trial. Find out why Q4 2025 data could be a game changer for muscle-preserving weight loss.
Can Dr. Reddy’s GLP-1 strategy position it as a key player in the global metabolic drug race?
Explore Dr. Reddy’s GLP‑1 pipeline, patent strategy, and emerging market focus—can the Hyderabad-based pharma firm lead India’s metabolic drug push?
How oral obesity drugs are changing treatment access: A look at semaglutide, amycretin, and orforglipron
Oral GLP-1 drugs like semaglutide, amycretin, and orforglipron are redefining obesity care. Explore trial data, payer impact, and what’s ahead for access and scale.
OrsoBio unveils ADA 2025 preclinical data showcasing dual-pathway obesity drug strategy with lean mass preservation
OrsoBio presents ADA 2025 data on TLC-6740 and TLC-1180 showing sustained fat loss and lean mass preservation in obesity models. Human trials underway.
How Novo Nordisk is building a post-semaglutide strategy: Inside its metabolic pipeline and innovation bets
Novo Nordisk pivots beyond semaglutide with amycretin, CagriSema, and oral GLP-1 therapies. See how it’s building its next-generation obesity drug platform.
How are GLP-1 drugs like Wegovy and Zepbound reshaping obesity care beyond weight loss in 2025?
GLP-1 drugs like Wegovy and Zepbound are reshaping obesity care in 2025, with benefits extending to cardiovascular, liver, and kidney health. Learn more now.